ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
CytomX Therapeutics Inc

CytomX Therapeutics Inc (CTMX)

1,15
0,03
(2,68%)
Geschlossen 14 Oktober 10:00PM
1,15
0,00
(0,00%)
Nach Börsenschluss: 1:31AM

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
1,15
Gebot
1,13
Fragen
1,15
Volumen
337.828
1,11 Tagesbereich 1,15
1,04 52-Wochen-Bereich 5,85
Marktkapitalisierung
Handelsende
1,12
Handelsbeginn
1,14
Letzter Handelszeitpunkt
Finanzvolumen
US$ 381.762
VWAP
1,13
Durchschnittliches Volumen (3 Mio.)
642.927
Ausgegebene Aktien
78.117.601
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-156,16
Gewinn pro Aktie (EPS)
-0,01
Erlöse
101,21M
Nettogewinn
-569k

Über CytomX Therapeutics Inc

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clini... CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Dover, Delaware, USA
Gegründet
-
CytomX Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CTMX. The last closing price for CytomX Therapeutics was US$1,12. Over the last year, CytomX Therapeutics shares have traded in a share price range of US$ 1,04 to US$ 5,85.

CytomX Therapeutics currently has 78.117.601 shares in issue. The market capitalisation of CytomX Therapeutics is US$87,49 million. CytomX Therapeutics has a price to earnings ratio (PE ratio) of -156.16.

CTMX Neueste Nachrichten

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today...

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that...

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1001.151.1851.1024139571.13995609CS
4-0.12-9.448818897641.271.291.1027414731.17781063CS
12-0.22-16.05839416061.371.511.096429271.22746929CS
26-0.95-45.23809523812.15.851.0937209093.6006055CS
52-0.12-9.448818897641.275.851.0421623213.38922434CS
156-3.72-76.3860369614.877.52991.0415017252.92898925CS
260-5.9-83.68794326247.0515.441.0411529493.93299631CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
CAMPCAMP4 Therapeutics Corporation
 10,75
(2.587,50%)
378,47k
TWGTop Wealth Group Holding Ltd
US$ 7,14
(233,64%)
154,23M
NIVFNewGenIvf Group Ltd
US$ 0,98
(63,42%)
58,51M
ATIFATIF Holdings Ltd
US$ 1,235
(58,33%)
3,85M
VERBVerb Technology Company Inc
US$ 7,91
(51,82%)
15,55M
BYUBAIYU Holdings Inc
US$ 0,299
(-35,28%)
11,11M
TURBTurbo Energy SA
US$ 2,1511
(-29,01%)
3,2M
SMSTDefiance Daily Target 1.5X Short MSTR ETF
US$ 7,898
(-23,62%)
993,33k
VEEAVeea Inc
US$ 3,27
(-23,24%)
284,95k
INHDInno Holdings Inc
US$ 3,74
(-22,41%)
257,75k
JTAIJet AI Inc
US$ 0,1009
(23,50%)
340,09M
CDTConduit Pharmaceuticals Inc
US$ 0,116
(13,28%)
270,97M
NVDANVIDIA Corporation
US$ 134,80
(-0,01%)
170,27M
LUXHLuxUrban Hotels Inc
US$ 0,0532
(5,35%)
165,94M
TWGTop Wealth Group Holding Ltd
US$ 7,14
(233,64%)
154,23M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock